Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464044 | 0.84 | BIRC5 (0.49) | FGFR1BIRC5TSHRMGLLRAB9A | |
| SCHEMBL6075112 | 0.84 | HPGD (0.52) | BIRC5HTTALDH1A1HPGDNPSR1 | |
| SCHEMBL30201534 | 0.82 | FGFR1 (0.56) | FGFR1TSHRKDM4EALDH1A1HPGD | |
| SCHEMBL3975054 | 0.82 | FGFR1 (0.60) | FGFR1TSHRMGLLHTTKDM4E | |
| SCHEMBL4604283 | 0.82 | FGFR1 (0.56) | FGFR1TSHRKDM4EALDH1A1HPGD | |
| SCHEMBL9057476 | 0.82 | MAPT (0.44) | FGFR1BIRC5TSHRMGLLKDM4E | |
| SCHEMBL29374301 | 0.81 | BIRC5 (0.59) | BIRC5TSHRMGLLRAB9AL3MBTL1 | |
| SCHEMBL7213172 | 0.81 | BIRC5 (0.59) | BIRC5TSHRMGLLRAB9AL3MBTL1 | |
| SCHEMBL26436188 | 0.80 | HTT (0.51) | FGFR1HTTALDH1A1MAPT | |
| SCHEMBL10295997 | 0.80 | BIRC5 (0.57) | BIRC5TSHRMGLLALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212056-B2 | Ligands for transition-metals and methods of use | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-07-03 | — | — | US | disclosed |
| US-20090326243-A1 | Ligands for transition-metals and methods of use | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-12-31 | — | — | US | disclosed |
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
| WO-1998037068-A1 | BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326243-A1 | Ligands for transition-metals and methods of use | PDK4, PDXK, PDK3 | FGFR1 181/4885BIRC5 1814/4885TSHR 1068/4885 |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | FGFR1 837/4885BIRC5 3072/4885TSHR 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.